North America Injectable Drug Industry Outlook from 2024 to 2034

Recording a y-o-y growth of 8.5%, injectable drug sales in North America are forecast to total US$ 209.2 billion in 2024. A healthy CAGR of 6.9% is on the horizon for the North America injectable drug industry, with total revenue reaching a staggering US$ 407.2 billion by 2034.

Analgesics remain the top-selling injectable drugs across North America, owing to their high adoption in pain management. The target segment is forecast to record a CAGR of 8.8% from 2024 to 2034.

North America Injectable Drug Industry Forecast

Attributes Key Insights
Base Value in 2023 US$ 192.8 billion
North America Injectable Drug Industry Size in 2024 US$ 209.2 billion
North America Injectable Drug Industry Value in 2034 US$ 407.2 billion
Value CAGR (2024 to 2034) 6.9%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

North America Injectable Drug Industry Overview

Injectable drugs such as antibiotics, antivirals, analgesics, corticosteroids, vasodilators, antipsychotics, and opioids are witnessing high demand across North America. This can be attributed to rising incidence of chronic disease and quick and effective action of injectables.

Injectable drugs are becoming versatile and effective means of delivering medication quickly. Their fast action, enhanced bioavailability, and higher effectiveness make them popular in managing a wide variety of medical conditions.

Healthcare professionals prefer injectable drugs, especially in complex cases, as they allow for accurate dosing and rapid biological response. Growing popularity of injectable drugs for treating chronic infections, diabetes, cancer, and pain will propel sales growth.

The rise of biologics like insulin, monoclonal antibodies, and gene therapies is opening new growth windows for injectable drug companies. Similarly, rising popularity of self-injectables due to their convenience will benefit the injectable drug industry in North America.

Sales remain particularly high for analgesic drugs owing to their adoption for pain management. These medications quickly and effectively relieve severe pain, making them highly sought-after in the region.

There are a handful of sterile injectable manufacturers with limited production capacity. Also, the manufacturing process is complicated and has large lead time. These factors have made the injectable drug industry prone to shortage.

As per the survey conducted by ASHP in March 2022, there was a shortage of certain important injectable drugs. The key finding of the survey showed prefilled 50% dextrose syringes, 0.9% saline syringes or vials, local anesthetic vials (with or without epinephrine), and prefilled epinephrine syringes were severely impacted by the shortage along with other medications.

To address this shortage, manufacturers are focusing on enhancing their production capacity. They are also collaborating with contract manufacturing organizations (CMOs) to reduce costs and save their time.

Historical Performance Vs. Future North America Injectable Drug Demand Outlook

Sales of injectable drugs in North America increased at a CAGR of 5.9% from 2019 to 2023. Total revenue at the end of 2034 reached around US$ 192.8 billion. Between 2024 and 2034, injectable drug demand in the region is forecast to surge at 6.9% CAGR.

Growing awareness about the advantages of injectables is a key factor propelling demand. Injectable drugs offer multiple benefits, including fast action and high effectiveness. This is making them popular among healthcare professionals and patients.

Another contributor to the industry expansion is the continuous drug approval and product launch. Top injectable drug manufacturers are constantly introducing new products targeting various therapeutic areas.

In 2022, the United States Food & Drug Administration (US FDA) approved over 100 injectable drugs. Also, in April 2023, Endo Pharmaceutical announced the launch of Argatroban injection through Premier's ProRx private-label program.

In January 2022, Hikma launched the diazepam injection, USP, in a single-dose prefilled syringe. This shows the harmony between the strategic moves adopted by companies and the supporting regulatory process, which is fueling the injectable drug industry.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Factors Boosting Growth of Injectable Drug Industry in North America

Rising trend of outsourcing drug development processes is emerging as a key factor boosting the industry. Injectable pharmaceutical companies are shifting toward contract development and manufacturing organizations for numerous reasons.

Outsourcing manufacturing allows companies to increase their production capacity and tackle the drug shortage within the industry. It also reduces the investment required for facility and maintaining the team of experts.

The growing adoption of generic injectable drugs is another factor boosting injectable drug industry growth in North America. According to the US FDA, 91% of all prescriptions are generic drugs in the United States.

In 2017, the FDA granted approval for 80 new orphan indications and further 53 approvals in 2020. Hence, the shift toward outsourcing manufacturing activities, increased adoption of generic drugs, and new approval of orphan drugs will create lucrative growth prospects for manufacturers.

Factors Limiting North America Injectable Drug Industry Growth

Despite the significant opportunity for injectable drug industry, the high operational costs of injectable drugs act as a restraint for the industry. These medications require complex equipment for manufacturing. This leads to high operating costs and high debt levels due to the purchase or rent-to-lease of capital equipment.

The elevated expenses can create challenges for patients, healthcare providers, and healthcare systems, potentially leading to restricted access and utilization of injectable therapies. Additionally, high drug prices may result in increased financial burdens on individuals and healthcare budgets, influencing treatment decisions and industry expansion.

The regulatory cost burden is also high as the United States Food and Drug Administration (FDA) mandates to maintain a high degree of care in not only manufacturing but also packaging, storage, and distribution. Some areas of high cost include maintaining sterility from bacterial and fungal contamination and stability issues (crystallization). This can limit industry expansion.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Country-wise Insights

The table below shows the estimated growth rates of different nations across North America. Canada is set to witness high injectable drug consumption, recording a CAGR of 8.7% through 2034.

Growth Outlook by Key Countries

Countries Value CAGR
United States 6.8%
Canada 8.7%

Rising Prevalence of Chronic Diseases Propelling Sales in the United States

The United States injectable drug industry has a bright future, with total valuation reaching US$ 202.88 billion in 2024. Emerging trends indicate injectable drug sales to rise at around 6.8% across the United States through 2034.

Growing incidence of chronic diseases, such as diabetes and cancer, is a key factor providing impetus for sales growth. Subsequently, escalating popularity of biologics, especially insulin and other cancer treatments, administered through injection will boost sales.

The United States has a well-established healthcare infrastructure which establishes its dominance in North America. According to the American Hospital Association (AHA), there are around 916,752 staffed beds in all United States hospitals and about 33,679,935 admissions.

The growing hospital admissions and high prevalence of chronic diseases are leading to increased use of injectable drugs, thereby pushing sales growth. Strong presence of top pharmaceutical giants is also improving the United States injectable drug industry share.

Canada to Present Lucrative Growth Opportunities to Injectable Drug Companies

Canada is emerging as a highly remunerative pocket for injectable drug manufacturers and distributors. A robust CAGR of 8.7% has been predicted for Canada's injectable drug industry between 2024 and 2034.

Canada has a stringent regulatory framework, and there is growing adoption of biologics. These complex molecules, often administered via injection, offer targeted therapies for various diseases. This is providing impetus for the growth of injectable drug industry in the country.

The ongoing innovations in drug delivery systems and rising burden of diseases are other factors behind the rising sales of injectable drugs. Similarly, favorable government support will aid in the expansion of the target industry.

Category-wise Insights

The section covers all the leading segments of North America’s injectable drug industry. By drug class, the analgesics segment is projected to witness a CAGR of 8.8% through 2034. In terms of route of administration, the intravenous (IV) injections segment is likely to showcase a 6.0% CAGR through 2034.

Analgesics Remain Highly Sought-after Drugs in North America

Growth Outlook by Drug Class

Drug Class Value CAGR
Antibiotics 5.1%
Antivirals 7.0%
Antifungal 9.4%
Antibacterial 4.8%
Analgesics 8.8%
Antipsychotic 7.6%
Opioids 4.1%
Local and General Anesthetics 7.8%
Anticoagulants 9.0%
Anticovasculants 7.7%
Muscle Relaxant 8.3%
Antihistamines 7.2%
Corticosteroids 4.4%
Calcium 6.1%
Cardiotonic 8.0%
Sympathomimetic 9.2%
Hormonal Contraceptive 4.7%
Intravenous Infusion 9.1%
Vasodilator 5.7%
Beta-blockers 4.6%
Vitamins 7.3%
Antiemetic 8.4%
Proton-Pump Inhibitors (PPIs) 4.2%
Chemotherapy Drugs 8.4%
Others 5.2%

Injectable analgesic drugs are in high demand across North America. This is attributable to growing need for pain management across different therapeutic areas. As per the latest analysis, the analgesics segment will display a CAGR of 8.8%, accounting for a revenue share of 12.6% in 2034.

Analgesics drugs like paracetamol, opioids, aspirin, and NSAIDS are the first line to treat many cases of pain management. Injectable analgesics are especially gaining popularity in North America due to their ability to quickly and effectively relieve severe or acute pain.

Intravenous Injections Remain Preferred Route of Administration

Growth Outlook by Route of Administration

Route of Administration Value CAGR
Intravenous (IV) Injections 6.0%
Intramuscular (IM) Injections 7.7%
Subcutaneous (SC) Injections 8.8%

Intravenous injections remain the gold standard route of administration in North America. This is due to its multiple benefits, including fast drug delivery and precision. This route of administration is ideal in situations where speed and accuracy are significant.

As per the latest report, the intravenous injections segment will continue to retain its dominance in North America, holding a share of 47.9% in 2024. Further, a CAGR of 6.0% is on the cards for the target segment.

Intravenous administration is a widely preferred route of administration in hospitals and by major surgeons. This is because it offers predictable bioavailability and precise dosage delivery.

In chronic cases where quick response is required, IV route is used. IV medications have the tendency to deliver life-saving drugs quickly and effectively in situations like heart attack, shock, and chronic infection.

Injectable Drugs Gaining High Prominence in Cancer Treatment

Growth Outlook By Therapeutic Area

Therapeutic Area Value CAGR
Pain Management 5.4%
Cardiovascular Disease 7.9%
Infectious Disease 5.9%
Allergy 6.8%
Gastrointestinal Disease 6.5%
Nutrition Deficiency 4.1%
Hematology Disorders 5.0%
Gynecology 7.3%
Cancer 9.8%

Injectable drug usage is rising rapidly in cancer treatments due to their fast and quick action. Courtesy of this, the target segment will probably thrive at 9.8% CAGR between 2024 and 2034.

Growing incidence of cancer in North America will lead to higher demand for cancer treatments, creating growth opportunities for injectable drug manufacturers. Similarly, rising importance of injectable drugs for cancer is set to accelerating segment growth.

According to the World Health Organization (WHO), the cancer burden is escalating in North America and other regions. This, in turn, is propelling demand for chemotherapy and other cancer treatments that use injectable drugs.

Chemotherapy is the most widely used treatment option for cancer patients. It involves administration of chemical agents through IV route to target cancerous cells. Hence, growing cancer prevalence and rise in chemotherapy will continue to give the cancer segment a slight edge over other therapeutic areas.

Competitive Landscape

Leading manufacturers of injectable drugs in North America are constantly investing in research and development to explore new drugs targeting various therapeutic areas. They are also exploring new drug delivery systems, including self-injectable options, as well as developing targeted therapies and biologics to stay ahead of the competition.

Several injectable drug companies are partnering and collaborating with contract manufacturing organizations (CMOs) to reduce costs and save time. Similarly, the North America injectable drug industry is witnessing strategies like acquisitions, distribution agreements, and mergers as players look to push their expertise and footprint.

Recent Developments in North America Injectable Drug Industry

  • In April 2023, Teva Pharmaceuticals MedinCell announced FDA approval of UZEDY extended-release injectable suspension to treat schizophrenia in adults.
  • In January 2020, Merck established a Strategic Oncology Collaboration with Taiho and Astex.
  • In January 2022, Sanofi and Exscientia collaborated to develop AI-driven pipeline of precision-engineered medicines.
  • In October 2022, Pfizer Inc. completed acquisition of Global Blood Therapeutics, Inc.

Key Coverage in North America Injectable Drug Industry Research Report

  • Adjacent Study on Global Sterile Injectable Drugs Market, North America Drug Delivery Market, Lyophilized Injectable Drugs, and Injectable Drug Delivery Technology Market
  • Detailed North America Pharmaceutical Market Analysis
  • Recently Approved Injectable Drugs in North America
  • Popular Sterile Injectable Drugs across North America
  • Factors Encouraging Adoption of Self-injectable Drugs
  • Expected Injectable Drug Delivery Market Size
  • Current Small Molecule Injectable Drugs Market Size vs. large Molecules Injectable Drugs Market Size
  • Injectable Drug Delivery Devices Global Market Report

North America Injectable Drug Industry Report Scope

Attribute Details
Industry Value in 2024 US$ 209.2 billion
Industry Size in 2034 US$ 407.2 billion
Growth Rate (2024 to 2034) 6.9% CAGR
Forecast Period 2024 to 2034
Historical Data Available for 2019 to 2023
Industry Analysis US$ billion for Value
Key Regions Covered North America
Key Countries Covered United States, Canada, and Mexico
Key Industry Segments Covered Drug Class, Route of Administration, Therapeutic Area, Molecule Type, and Distribution Channel.
Key Companies Profiled
  • Pfizer Inc.
  • GlaxoSmithKline Plc.
  • Sanofi
  • Merck & Co., Inc.
  • Eli Lilly and Company
  • Boehringer Ingelheim International GmbH
  • Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
  • Bayer AG
  • Amgen Inc.
  • Novo Nordisk A/S
  • Takeda Pharmaceutical Company Limited
  • Eisai Co., Ltd.
  • Sandoz (Novartis AG)
  • Teva Pharmaceutical Industries Ltd.
  • Cipla Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Lupin Pharmaceuticals
  • Hikma Pharmaceuticals PLC
  • Viatris Inc. (Mylan N.V)
  • Endo International (Par Pharmaceutical )
  • Aspen Pharmacare
  • Aurobindo Pharma
Report Coverage Industry Forecast, Competition Intelligence, DROT Analysis, Industry Dynamics and Challenges, Strategic Growth Initiatives

North America Injectable Drug Industry Segmentation

By Drug Class:

  • Antibiotics
  • Antivirals
  • Antifungal
  • Antibacterial
  • Analgesics
  • Antipsychotic
  • Opioids
  • Local and General Anesthetics
  • Anticoagulants
  • Anticovasculants
  • Muscle Relaxant
  • Antihistamines
  • Corticosteroids
  • Calcium
  • Cardiotonic
  • Sympathomimetic
  • Hormonal Contraceptive
  • Intravenous Infusion
  • Vasodilator
  • Beta-blockers
  • Vitamins
  • Antiemetic
  • Proton-Pump Inhibitors (PPIs)
  • Chemotherapy Drugs
  • Others

By Route of Administration:

  • Intravenous (IV) Injections
  • Intramuscular (IM) Injections
  • Subcutaneous (SC) Injections

By Therapeutic Area:

  • Pain Management
  • Cardiovascular Disease
  • Infectious Disease
  • Allergy
  • Gastrointestinal Disease
  • Nutrition Deficiency
  • Hematology Disorders
  • Gynecology
  • Cancer

By Molecule Type:

  • Small Molecules
  • Large Molecules

By Distribution Channel:

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Long Term Care Facilities
  • Retail Pharmacy Chains
  • Online Pharmacies/Mail Order Pharmacies

By Country:

  • United States
  • Canada

Frequently Asked Questions

How big is the North America injectable drug industry?

The North America industry value is set to total US$ 209.2 billion in 2024.

What is the growth projection for North America industry?

The North America industry size is forecast to reach US$ 407.2 billion by 2034.

What is the demand outlook for injectable drugs?

Injectable drug demand in North America is set to rise at 6.9% CAGR.

Which is the most popular drug class in North America?

With a 10.8% value share, analgesics remain a popular drug class.

What was the historical CAGR for the North America industry?

The North America industry increased at a 5.9% CAGR from 2019 to 2023.

How big is the injectable industry in the United States?

The United States injectable drug industry size reached US$ 187.06 billion in 2023.

Table of Content
1. Executive Summary
    1.1. Industry Outlook
    1.2. Demand Side Trends
    1.3. Supply-Side Trends
    1.4. Analysis and Recommendations
2. Industry Overview
    2.1. Industry Coverage / Taxonomy
    2.2. Industry Definition / Scope / Limitations
    2.3. Inclusions and Exclusions
3. Key Industry Trends
    3.1. Key Trends Impacting the Industry
    3.2. Development/Innovation Trends
    3.3. Industry Trends
4. Value Added Insights
    4.1. Product Adoption/ Usage Analysis
    4.2. Disease Epidemiology
    4.3. List of Competitive Generic Therapy Approvals
    4.4. List of Approved Drug in United States
    4.5. Pipeline Assessment
    4.6. Porter’s Analysis
    4.7. PESTEL Analysis
    4.8. Supply Chain Analysis
    4.9. Regulatory Landscape
    4.10. Reimbursement Guidelines
    4.11. Parent Industry Analysis
5. Industry Background
    5.1. Macro-Economic Factors
        5.1.1. Global Healthcare Expenditure Outlook
        5.1.2. Global R&D Funding, by Region
        5.1.3. Pharmaceutical Spending, by Key Countries
    5.2. Forecast Factors - Relevance & Impact
        5.2.1. Historical Growth of Key Players
        5.2.2. Industry Consolidation Activities
        5.2.3. Increasing FDA Approvals
        5.2.4. Rising Prevalence of Cancer and Cardiovascular Diseases
        5.2.5. Increasing Adoption of
        5.2.6. Rising Demand for Small Molecule Injectable for Pain Management
        5.2.7. Cost Effectiveness of
        5.2.8. Increasing Research & Development
        5.2.9. Regulatory Framework
        5.2.10. Key Strategic Developments By Industry Players
    5.3. Industry Dynamics
        5.3.1. Drivers
        5.3.2. Restraints
        5.3.3. Opportunity Analysis
6. Industry Demand Value or Size (US$ billion) Analysis 2019 to 2023 and Forecast, 2024 to 2034
    6.1. Historical Industry Value (US$ billion) Analysis, 2019 to 2023
    6.2. Current and Future Industry Value (US$ billion) Projections, 2024 to 2034
        6.2.1. Y-o-Y Growth Trend Analysis
        6.2.2. Absolute $ Opportunity Analysis
    6.3. Revenue Opportunity Scenario
7. Industry Analysis 2019 to 2023 and Forecast 2024 to 2034, By Drug Class
    7.1. Introduction / Key Findings
    7.2. Historical Industry Size (US$ billion) Analysis By Drug Class, 2019 to 2023
    7.3. Current and Future Industry Size (US$ billion) Analysis and Forecast By Drug Class, 2024 to 2034
        7.3.1. Antibiotics
        7.3.2. Antivirals
        7.3.3. Antifungal
        7.3.4. Antibacterial
        7.3.5. Analgesics
        7.3.6. Antipsychotic
        7.3.7. Opioids
        7.3.8. Local and General Anesthetics
        7.3.9. Anticoagulants
        7.3.10. Anticovasculants
        7.3.11. Muscle Relaxant
        7.3.12. Antihistamines
        7.3.13. Corticosteroids
        7.3.14. Calcium
        7.3.15. Cardiotonic
        7.3.16. Sympathomimetic
        7.3.17. Hormonal Contraceptive
        7.3.18. Intravenous Infusion
        7.3.19. Vasodilator
        7.3.20. Beta-blockers
        7.3.21. Vitamins
        7.3.22. Antiemetic
        7.3.23. Proton-Pump Inhibitors (PPIs)
        7.3.24. Chemotherapy Drug
        7.3.25. Others
    7.4. Industry Attractiveness Analysis By Drug Class
8. Industry Analysis 2019 to 2023 and Forecast 2024 to 2034, By Route of Administration
    8.1. Introduction / Key Findings
    8.2. Historical Industry Size (US$ billion) By Route of Administration, 2019 to 2023
    8.3. Current and Future Industry Size (US$ billion) Analysis and Forecast By Route of Administration, 2024 to 2034
        8.3.1. Intravenous (IV) injections
        8.3.2. Intramuscular (IM) injections
        8.3.3. Subcutaneous (SC) injections
    8.4. Industry Attractiveness Analysis By Route of Administration
9. Industry Analysis 2019 to 2023 and Forecast 2024 to 2034, By Therapeutic Area
    9.1. Introduction / Key Findings
    9.2. Historical Industry Size (US$ billion) By Therapeutic Area, 2019 to 2023
    9.3. Current and Future Industry Size (US$ billion) Analysis and Forecast By Therapeutic Area, 2024 to 2034
        9.3.1. Pain Management
        9.3.2. Cardiovascular Disease
        9.3.3. Infectious Disease
        9.3.4. Allergy
        9.3.5. Gastrointestinal Disease
        9.3.6. Nutrition Deficiency
        9.3.7. Hematology Disorders
        9.3.8. Gynecology
        9.3.9. Cancer
    9.4. Industry Attractiveness Analysis By Therapeutic Area
10. Industry Analysis 2019 to 2023 and Forecast 2024 to 2034, By Molecule Type
    10.1. Introduction / Key Findings
    10.2. Historical Industry Size (US$ billion) By Molecule Type, 2019 to 2023
    10.3. Current and Future Industry Size (US$ billion) Analysis and Forecast By Molecule Type, 2024 to 2034
        10.3.1. Small Molecules
        10.3.2. Large Molecules
    10.4. Industry Attractiveness Analysis By Molecule Type
11. Industry Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel
    11.1. Introduction / Key Findings
    11.2. Historical Industry Size (US$ billion) By Distribution Channel, 2019 to 2023
    11.3. Current and Future Industry Size (US$ billion) Analysis and Forecast By Distribution Channel, 2024 to 2034
        11.3.1. Hospital
        11.3.2. Clinics
        11.3.3. Ambulatory Surgical Centers
        11.3.4. Long Term Care Facilities
        11.3.5. Retail Pharmacy Chains
        11.3.6. Online Pharmacies/Mail Order Pharmacies
    11.4. Industry Attractiveness Analysis By Distribution Channel
12. Industry Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
    12.1. Introduction
    12.2. Historical Industry Size (US$ billion) Trend Analysis by Country, 2019 to 2023
    12.3. Current Industry Size (US$ billion) Analysis and Forecast by Country, 2024 to 2034
        12.3.1. United States
        12.3.2. Canada
    12.4. Industry Attractiveness Analysis By Country
13. United States Industry Analysis 2019 to 2023 and Forecast 2024 to 2034
    13.1. Introduction
    13.2. Historical Industry Size (US$ billion) Trend Analysis by Industry Taxonomy, 2019 to 2023
    13.3. Current and Future Industry Size (US$ billion) Analysis and Forecast by Industry Taxonomy, 2024 to 2034
        13.3.1. By Drug Class
        13.3.2. By Route of Administration
        13.3.3. By Therapeutic Area
        13.3.4. By Molecule Type
        13.3.5. By Distribution Channel
    13.4. Industry Attractiveness Analysis
        13.4.1. By Drug Class
        13.4.2. By Route of Administration
        13.4.3. By Therapeutic Area
        13.4.4. By Molecule Type
        13.4.5. By Distribution Channel
    13.5. Drivers and Restraints - Impact Analysis
14. Canada Industry Analysis 2019 to 2023 and Forecast 2024 to 2034
    14.1. Introduction
    14.2. Historical Industry Size (US$ billion) Trend Analysis by Industry Taxonomy, 2019 to 2023
    14.3. Current and Future Industry Size (US$ billion) Analysis and Forecast by Industry Taxonomy, 2024 to 2034
        14.3.1. By Drug Class
        14.3.2. By Route of Administration
        14.3.3. By Therapeutic Area
        14.3.4. By Molecule Type
        14.3.5. By Distribution Channel
    14.4. Industry Attractiveness Analysis
        14.4.1. By Drug Class
        14.4.2. By Route of Administration
        14.4.3. By Therapeutic Area
        14.4.4. By Molecule Type
        14.4.5. By Distribution Channel
    14.5. Drivers and Restraints - Impact Analysis
15. Industry Structure Analysis
    15.1. Industry Analysis by Tier of Companies
    15.2. Industry Share Analysis of Top Players (%)
    15.3. Industry Presence Analysis
16. Competition Analysis
    16.1. Competition Dashboard
    16.2. Branding and Promotional Strategies by Industry Players
    16.3. Key Development Analysis
    16.4. Competition Benchmarking
    16.5. Competition Deep Dive
        16.5.1. Pfizer Inc.
            16.5.1.1. Overview
            16.5.1.2. Product Portfolio
            16.5.1.3. Pipeline Products
            16.5.1.4. Key Financials
            16.5.1.5. SWOT Analysis
            16.5.1.6. Key Developments
            16.5.1.7. Sales Footprint
            16.5.1.8. Strategy Overview
                16.5.1.8.1. Industrying Strategy
                16.5.1.8.2. Product Strategy
                16.5.1.8.3. Channel Strategy
        16.5.2. GlaxoSmithKline Plc.
        16.5.3. Sanofi
        16.5.4. Merck & Co., Inc.
        16.5.5. Eli Lilly and Company
        16.5.6. Boehringer Ingelheim International GmbH
        16.5.7. Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
        16.5.8. Bayer AG
        16.5.9. Amgen Inc.
        16.5.10. Novo Nordisk A/S
        16.5.11. Takeda Pharmaceutical Company Limited
        16.5.12. Eisai Co., Ltd.
        16.5.13. Sandoz (Novartis AG)
        16.5.14. Teva Pharmaceutical Industries Ltd.
        16.5.15. Cipla Ltd.
        16.5.16. Sun Pharmaceutical Industries Ltd.
        16.5.17. Lupin Pharmaceuticals
        16.5.18. Hikma Pharmaceuticals PLC
        16.5.19. Viatris Inc. (Mylan N.V)
        16.5.20. Endo International (Par Pharmaceutical)
        16.5.21. Aspen Pharmacare
        16.5.22. Aurobindo Pharma
17. Assumptions and Acronyms Used
18. Research Methodology
Recommendations

Healthcare

Injectable Drug Market

March 2024

REP-GB-15073

306 pages

Healthcare

Small-Molecule Injectable Market

June 2023

REP-GB-14117

306 pages

Healthcare

Pain Therapeutic Injectables Market

April 2023

REP-GB-17090

425 pages

Healthcare

Generic Injectable Market

March 2023

REP-GB-6051

324 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Injectable Drug Industry Analysis in North America

Schedule a Call